![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biospace.com/article/zentalis-hit-with-fda-partial-clinical-hold-on-three-cancer-studies-following-two-patient-deaths-/
https://www.globenewswire.com/news-release/2024/05/07/2876560/0/en/Zentalis-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Operational-Progress.html
https://www.globenewswire.com/news-release/2024/04/02/2856461/0/en/Zentalis-Pharmaceuticals-to-Highlight-Preclinical-Data-Demonstrating-that-WEE1-Inhibitor-Azenosertib-Exerts-Synergistic-Anti-tumor-Activity-with-KRAS-G12C-Inhibitors-at-AACR-Annual.html
https://www.globenewswire.com/news-release/2023/06/06/2682584/0/en/Zentalis-Announces-Intermittent-Azenosertib-Monotherapy-Dosing-Nearly-Doubles-Efficacy-Over-Continuous-Dosing.html
https://www.globenewswire.com/news-release/2023/05/25/2676791/0/en/Zentalis-Announces-Presentation-of-Positive-Phase-1b-Data-Demonstrating-Durable-Responses-and-Favorable-Safety-Profile-of-Azenosertib-in-Combination-with-Chemotherapy-at-the-2023-A.html
https://www.globenewswire.com/news-release/2023/04/26/2655296/0/en/Zentalis-to-present-positive-clinical-data-in-ovarian-cancer-combining-azenosertib-and-chemotherapy-including-clinical-support-for-Cyclin-E1-expression-as-predictive-marker-for-cli.html